• On 17 November 2021, the Food and Drug Administration (FDA) issued authorization (amended on 30 June 2022) granting Farberco Life Sciences Inc. the emergency use approval of SARS-CoV-2 rS Protein Nanoparticle Vaccine [Covovax].
  
  

Product Information
 English

• For more information on reporting side effects, click here.